TREX1 and neoplasm: Importantly, although multiple lines of investigation in academia and industry are pursuing the use of STING agonists as a therapeutic strategy to enhance tumor immunogenicity, it is tempting to speculate that direct inhibition of TREX1, acting upstream of STING, may produce an added benefit to amplify the signal producing a more robust interferon signal.